2025 – Page 2 – Biosortia

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal

September 2 2025

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal (Aug 28, 2025) by Darren Incorvaia. As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration with Replicate Bioscience, potentially

Host: Julio Martinez

Guest: Ross Youngs

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

August 29 2025
Video - Date: 08/28/2025
Length: 29.44

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

KEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing

July 30 2025

Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing (Jul 30, 2025) by James Waldron. Summary Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra The GLP-1 drug, dubbed SYH2086, has been developed by China’s CSPC Pharmaceutical. Preclinical

Novartis puts $1B on the line to court preclinical biotech Matchpoint

July 25 2025

Novartis puts $1B on the line to court preclinical biotech Matchpoint (July 24, 2025) by Gabrielle Masson. Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult to treat. The exclusive option and licensing pact covers the development and commercialization

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal

July 25 2025

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal (July 24, 2025) by Gabrielle Masson. Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small-molecule drug class. The pact’s potential value includes an undisclosed upfront payment amount and equity investment in the

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

June 26 2025

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal (June 26, 2025) by Annalee Armstrong. Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria. Minovia Therapeutics, an Israeli biotech hoping to get to the root causes of disease and aging, is planting itself onto the Nasdaq through a special purpose acquisition

Host: Dario Priolo

Guest: Ross Youngs

UNLOCKING THE TRILLION DOLLAR OPPORTUNITY IN MICROBIOME MINING

June 12 2025
Video - Date: 05/19/2025
Length: 33 min

Summary – Ross has developed proprietary technology to mine microbiomes, already discovering 110,000+ novel small molecules with potential applications across pharmaceuticals, agriculture, and beyond.

Why investors should tune in:

– First-mover advantage in an untapped market
– Technology validated by Los Alamos National Lab
– Platform business model with multiple revenue streams
– Potential to generate 4X the human knowledge on microbial molecules annually

Ross brings exceptional credentials as a serial entrepreneur who’s built Inc. 500 companies and secured backing from DARPA, NIH, and major research institutions.

Host: Joseph Mallo

Guest: Ross Youngs

LEVERAGING ADVANCED TECHNOLOGY

June 12 2025
Video - Date: 01/22/2025
Length: 33 min

Summary – Join us for an inspiring episode of Mastering the Numbers as host Joe Mallo sits down with Ross Youngs, the visionary founder and CEO of Biosortia. In this in-depth conversation, Ross shares his journey of groundbreaking innovation, from his early days in plastics manufacturing to revolutionizing drug discovery. Learn how Biosortia is leveraging advanced technology and natural resources to access molecules that could transform medicine, agriculture, and cosmetics. Ross also dives into the challenges of scaling a startup, the importance of partnerships, and how perseverance led to game-changing advancements in their mission to serve the world’s most critical needs. Discover how Biosortia is breaking barriers by unlocking 100% of nature’s molecular secrets, a feat supported by top institutions like DARPA, ARPA-E, and Los Alamos National Lab. Ross discusses the potential of their technology to reduce pharmaceutical costs, foster global health innovation, and fuel competition in critical markets. This is a must-watch for entrepreneurs, scientists, and anyone curious about the future of biotechnology.